

# APPENDIX F



IND 57,005

Novartis Pharmaceuticals Corporation  
Attention: Henry Weidmuller, Associate Director  
Drug Regulatory Affairs  
59 Route 10  
East Hanover, NJ 07936-1080

OCT 30 1998

Dear Mr. Weidmuller:

We acknowledge receipt of your Investigational New Drug Application (IND) submitted pursuant to section 505(i) of the Federal Food, Drug, and Cosmetic Act. Please note the following identifying data:

IND Number Assigned: 57,005

Sponsor: Novartis Pharmaceuticals Corporation

Name of Drug: ERL080A

Date of Submission: September 30, 1998

Date of Receipt: October 1, 1998

RECEIVED

NOV 11 1998

DRA FILES

Studies in humans may not be initiated until 30 days after the date of receipt shown above. If, within the 30-day waiting period, we identify deficiencies in the IND that require correction before human studies begin or that require restriction of human studies until correction, we will notify you immediately that the study may not be initiated ("clinical hold") or that certain restrictions must be placed on it. In the event of such notification, you must continue to withhold, or to restrict, such studies until you have submitted material to correct the deficiencies, and we have notified you that the material you submitted is satisfactory.

It has not been our policy to object to a sponsor, upon receipt of this acknowledgement letter, either obtaining supplies of the investigational drug or shipping it to investigators listed in the IND. However, if the drug is shipped to investigators, they should be reminded that studies may not begin under the IND until 30 days after the IND receipt date or later if the IND is placed on clinical hold.

As sponsor of this IND, you are responsible for compliance with the Federal Food, Drug, and Cosmetic Act and the implementing regulations (Title 21 of the Code of Federal Regulations). Those responsibilities include (1) reporting any unexpected fatal or life-threatening adverse experience associated with use of the drug by telephone or fax no later than 7 calendar days after initial receipt of the information (21 CFR 312.32(c)(2)); (2) reporting any adverse

experience with use of the drug that is both serious and unexpected in writing within 15 calendar days of initial receipt of the information (21 CFR 312.32(c)(1)); and (3) submitting annual progress reports (21 CFR 312.33).

Please forward all future communications concerning this IND in triplicate, identified by the above IND number, and addressed as follows:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Special Pathogen and  
Immunologic Drug Products, HFD-590  
Attention: Document Control Room  
5600 Fishers Lane  
Rockville, Maryland 20857

Should you have any questions concerning this submission, please contact Dolores Bernato at (301) 827-2127.

Sincerely,

*Ellen C. Frank*

Ellen C. Frank, R.Ph.  
Chief, Project Management Staff  
Division of Special Pathogen and  
Immunologic Drug Products, HFD-590  
Office of Drug Evaluation  
Center for Drug Evaluation and Research